KRAS and colorectal neoplasm: While the concordant BRAF mutation and the MSI status were observed in 100% (18 of 18) paired samples of primary colorectal tumours and corresponding ovarian metastases, the KRAS mutation concordance was observed in 83.3% (15 of 18) of them.